Share on StockTwits

Shares of Bristol-Myers Squibb (NYSE:BMY) have been given an average recommendation of “Buy” by the seventeen brokerages that are presently covering the stock, AnalystRatings.NET reports. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and ten have assigned a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $55.12.

Shares of Bristol-Myers Squibb (NYSE:BMY) traded up 1.10% during mid-day trading on Tuesday, hitting $47.103. 2,371,510 shares of the company’s stock traded hands. Bristol-Myers Squibb has a 52-week low of $41.11 and a 52-week high of $57.49. The stock’s 50-day moving average is $49.66 and its 200-day moving average is $51.73. The company has a market cap of $78.058 billion and a price-to-earnings ratio of 26.93.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $0.46 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.43 by $0.03. The company had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.89 billion. During the same quarter in the prior year, the company posted $0.41 earnings per share. The company’s quarterly revenue was down .5% on a year-over-year basis. On average, analysts predict that Bristol-Myers Squibb will post $1.78 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on BMY shares. Analysts at Credit Suisse reiterated an “outperform” rating on shares of Bristol-Myers Squibb in a research note on Thursday, June 5th. They now have a $46.59 price target on the stock, down previously from $59.00. Separately, analysts at Morgan Stanley reiterated an “overweight” rating on shares of Bristol-Myers Squibb in a research note on Thursday, May 15th. They now have a $60.00 price target on the stock. Finally, analysts at Citigroup Inc. cut their price target on shares of Bristol-Myers Squibb from $60.00 to $55.00 in a research note on Thursday, May 15th. They now have a “market perform” rating on the stock.

Bristol-Myers Squibb Company (NYSE:BMY) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.